Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Ann Oncol 2017; 28: 761–768 (doi: 10.1093/annonc/mdw695)

In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga:

JB has performed consulting and/or advisory work for Grail, Roche, Lilly, Novartis. He has stock or other ownership interests in Grail.